Literature DB >> 31853537

Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.

Oyunbileg Magvanjav1,2, Rhonda M Cooper-Dehoff1,3, Caitrin W McDonough1, Yan Gong1, William R Hogan4, Julie A Johnson1,3.   

Abstract

BACKGROUND: Specific combinations of two drug classes are recommended in a variety of clinical situations in the management of hypertension. These preferred combinations are based on complimentary blood pressure (BP) lowering mechanisms or benefit for a concomitant disease.
METHODS: Using electronic health records (EHRs) data from 27,579 ambulatory hypertensive patients, we investigated antihypertensive therapy prescribing patterns and associations of preferred two drug classes with BP control.
RESULTS: Overall, BP control, defined as BP <140/90 mm Hg, was 65% among treated patients. Preferred dual antihypertensive therapy was prescribed in 55% of patients with uncomplicated hypertension, 49% of patients with diabetes, and 47% of patients with a history of myocardial infarction (MI); these prescribing frequencies of preferred combinations were not explained by worse BP control on those combinations. In fact, we found suggestive evidence of association between prescribing of preferred two drug classes and improved BP control among post-MI (OR: 1.21, 95% CI: 0.99-1.48, P = 0.061) and uncomplicated hypertensive (OR: 1.11, 95% CI: 0.98-1.26, P = 0.089) patients.
CONCLUSIONS: Prescribing of guideline-recommended antihypertensive drug classes for concomitant diseases is suboptimal and prescribing of preferred/optimized drug class combinations was moderate. We did not find a clear association between the use of optimized drug class combinations and greater BP control. Overall, using EHR data, we identified potential opportunities for re-examining prescribing practices with implications for clinical decision support and healthcare improvement at the community and health system-wide levels. © American Journal of Hypertension, Ltd 2019. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antihypertensive agents; blood pressure; blood pressure control; combination therapy; drug prescribing; electronic health records; hypertension

Mesh:

Substances:

Year:  2020        PMID: 31853537      PMCID: PMC7109351          DOI: 10.1093/ajh/hpz196

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  41 in total

1.  Evaluation of the agreement between guidelines and initial antihypertensive drug treatment using a national health care reimbursement database.

Authors:  Pierre Meneton; Philippe Ricordeau; Alain Weill; Philippe Tuppin; Solène Samson; Hubert Allemand; Pierre Durieux; Joël Ménard
Journal:  J Eval Clin Pract       Date:  2011-01-30       Impact factor: 2.431

2.  Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.

Authors:  Mohammed Siddiqui; Tanja Dudenbostel; David A Calhoun
Journal:  Can J Cardiol       Date:  2015-07-08       Impact factor: 5.223

3.  2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman
Journal:  J Am Coll Cardiol       Date:  2014-09-23       Impact factor: 24.094

4.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

Review 5.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

6.  Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice.

Authors:  Giovanni Corrao; Federica Nicotra; Andrea Parodi; Antonella Zambon; Franca Heiman; Luca Merlino; Ida Fortino; Giancarlo Cesana; Giuseppe Mancia
Journal:  Hypertension       Date:  2011-08-08       Impact factor: 10.190

7.  Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; In Lu A Liu; David A Calhoun; Elizabeth A McGlynn; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2013-10       Impact factor: 7.616

8.  Antihypertensive treatment and blood pressure control relative to hypertension treatment guidelines.

Authors:  Christopher G Rowan; John Rick Turner; Ankit Shah; Jeffrey A Spaeder
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-08-29       Impact factor: 2.890

9.  Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination.

Authors:  L M Wing; J P Chalmers; M J West; A E Russell; M J Morris; M D Cain; A J Bune; D O Southgate
Journal:  Clin Exp Hypertens A       Date:  1988

Review 10.  Electronic health records to facilitate clinical research.

Authors:  Martin R Cowie; Juuso I Blomster; Lesley H Curtis; Sylvie Duclaux; Ian Ford; Fleur Fritz; Samantha Goldman; Salim Janmohamed; Jörg Kreuzer; Mark Leenay; Alexander Michel; Seleen Ong; Jill P Pell; Mary Ross Southworth; Wendy Gattis Stough; Martin Thoenes; Faiez Zannad; Andrew Zalewski
Journal:  Clin Res Cardiol       Date:  2016-08-24       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.